SELLAS Life Sciences expands SLS009 clinical program in frontline AML.
ByAinvest
Wednesday, Jan 14, 2026 8:38 am ET1min read
SLS--
SELLAS Life Sciences Group has entered into an agreement with IMPACT-AML, a European collaborative initiative, to evaluate SLS009, a CDK9 inhibitor, in a clinical study. The study will expand SLS009's clinical program into frontline AML, enabling broader patient enrollment in the US and Europe. US enrollment is planned for Q1 2026, with European enrollment anticipated in Q2 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet